Catecholaminergic activation of myocardial ␤-adrenergic receptors (␤AR) is the principle mechanism regulating cardiac function. Agonists desensitize ␤AR through G protein-coupled receptor kinase-mediated uncoupling and ␤-arrestin-mediated internalization. Although inhibition of myocardial G protein-coupled receptor kinase-2 enhances cardiac function and reverses heart failure, pathophysiological effects of modulated ␤AR internalization͞re-cycling are unknown. We used mutation and transgenic expression of Rab4, which regulates vesicular transport of heptahelical receptors to plasma membranes, to interrogate in vivo ␤AR trafficking and cardiac function. Expression of constitutively active Rab4 Q72L had no effects on cardiac structure or function, but dominant inhibitor Rab4 S27N impaired responsiveness to endogenous and exogenous catecholamines. To relate ␤AR trafficking to diminished cardiac function, Rab4 mutant mice were crossbred with mice overexpressing human ␤2AR. In unstimulated ␤2AR overexpressors, ␤2AR localized to heavier endosomes and translocated to lighter, caveolin-rich fractions after isoproterenol stimulation. Coexpression of ␤2AR with activated Rab4 Q72L caused loss of receptors from heavier endosomes while retaining normal inotropy. In contrast, coexpression of ␤2AR with inhibitory Rab4 S27N mimicked isoproterenol-induced receptor redistribution to caveolae, with diminished cardiac inotropy. Rab4 inhibition alone prevented resensitization after isoproterenol-induced in vivo adrenergic desensitization. Confocal and ultrastructural analyses revealed bizarre vesicular structures and abnormal accumulation of ␤2AR in the sarcoplasm and subsarcollema of Rab4 S27N, but not Q72L, mice. These data provide evidence for constant bidirectional sarcollemal-vesicular ␤AR trafficking in the in vivo heart and show that Rab4-mediated recycling of internalized ␤AR is necessary for normal cardiac catecholamine responsiveness and resensitization after agonist exposure.
A critical regulator of minute-by-minute cardiac function is the ␤-adrenergic receptor (␤AR). In response to acute physical or emotional stress, stimulation of myocardial ␤AR by circulating epinephrine or locally released norepinephrine increases cardiac contractility, heart rate, and blood flow to vital organs (1) . In chronic heart failure, activation of this pathway to compensate for cardiac insufficiency is defective, resulting in further increased sympathetic outflow and myocardial catecholamine toxicity (2, 3) . Specific ␤AR abnormalities that have been identified in heart failure include receptor down-regulation and uncoupling from signaling effectors (4, 5) . The therapeutic efficacy of pharmacological ␤AR blockade in heart failure has been linked to reversal of these abnormalities (6) .
Agonist-mediated uncoupling of ␤AR signaling involves Gprotein receptor kinase (GRK)-mediated phosphorylation events (7, 8) , whereas down-regulation of receptors is a ␤-arrestin-dependent process of transvesicular receptor internalization and trafficking (9) . ␤AR move from plasma membranes into endosomal structures where they are either targeted for lysosomal degradation or recycled as fully functional receptors by vesicular trafficking back to plasma membranes (resensitization) (10) . Although the roles for GRK-mediated ␤AR receptoreffector uncoupling in cardiac health and disease have been established (11) (12) (13) (14) , the pathophysiological roles of modulated ␤AR receptor internalization͞recycling have not been defined, largely because suitable in vivo experimental models do not exist. Herein, we used Rab-GTPases, regulators of inter-vesicular membrane transport (15) , to define effects of modulated ␤AR trafficking in the in vivo heart. These studies indicate that bidirectional sarcolemmal-vesicular ␤AR trafficking occurs continuously in the healthy heart and is necessary for normal baseline adrenergic responsiveness and resensitization after catecholamine exposure.
Methods
Generation of Mutant Rab4 Transgenic Mice. Transgenic mice used the ␣-myosin heavy chain (MHC) promoter to express constitutively active (GTPase deficient) Q72L or dominant inhibitory (non-GTP-binding) S27N Rab4 mutants (16) , identified by genomic Southern analysis of tail clip DNA. Human ␤2AR (h-␤2AR) transgenic mice were created by using an attenuated ␣-MHC promoter (17) as previously described (18) . Animals were treated in accordance with approved University of Cincinnati Institutional Animal Care and Use Committee protocols. stolic and systolic dimensions, from which fractional shortening was derived. Pulsed wave Doppler was used to measure aortic ejection time and calculate velocity of circumferential shortening (Vcf). Invasive hemodynamic studies were performed on anesthetized, spontaneously breathing 8-to 12-week-old transgenic mice and their NTG littermate controls (17, 18) .
Histopathology, Confocal Immunohistochemistry, and Ultrastructural
Studies. Histopathological examination was performed on Masson's trichrome stained sections. For immunofluorescence, deparafinized sections underwent antigen retrieval by heating and were immunolabeled with anti-␤2AR, goat anti-rabbit IgG͞ Alexa Fluor 488, and phalloidin͞Alexa Fluor 568 (Molecular Probes). Ultrastructural examination was as described (20) .
Statistical Analysis. Results are mean Ϯ SE. Experimental groups were compared by using Student's t test or one-way ANOVA. A Bonferroni test was used for post hoc comparisons, with P Ͻ 0.05 significant.
Results
In vivo models for gain-and-loss of myocardial Rab4 function were created by cardiomyocyte-specific transgenic expression of activated (Q72L) and inhibitory (S27N) Rab4 mutants (15, 16) . Multiple lines of both transgenes were grossly normal for 1 year. In contrast to the cardiomyopathy of Rab1 overexpression (20) , Rab4 mutants had minimal cardiac effects. Heart weights were similar between NTG (134 Ϯ 9 mg, n ϭ 7), Rab4 Q72L (151 Ϯ 4 mg, n ϭ 10), and Rab4 S27N (143 Ϯ 9 mg, n ϭ 13). Northern analysis showed no abnormalities of hypertrophy-associated genes, and histological appearances were normal (data not shown). For the current studies, Rab4 mutants were expressed at approximately the same levels (Fig. 1A) and did not affect myocardial expression of other Rabs (Fig. 1 A) , G proteins (Fig.  1B) , or GRK2 (data not shown).
Functional assays revealed a phenotype specific for Rab4 inhibition. Dominant inhibition of Rab4 (S27N mice) diminished echocardiographic left ventricular ejection fraction by 16% and Vcf by 22%, compared with NTG or Q72L mice ( Fig.  1C and Table 1 ). Given that conscious echocardiography induces a hyperadrenergic state, the consequences of infusing the nonselective ␤AR agonist isoproterenol were assessed by invasive hemodynamics. Left ventricular systolic function (peak ϩ dP͞dt) of both Rab4 mutant mice was normal at baseline but was diminished by Ϸ25% at high isoproterenol doses in S27N mice ( Fig. 1C Because Rab4 regulates endosomal sorting and recycling of transferrin receptors (21, 22) , we tested whether diminished ␤AR sensitivity of Rab4 S27N hearts was from disruption of ␤AR trafficking and impaired accessibility to signaling effectors. ␤AR subcellular distribution was examined in Rab4 mutant mouse hearts by crossbreeding with transgenic mice overexpressing myocardial h-␤2AR as a marker. Because massive overexpression of h-␤2AR can cause a fibrotic cardiomyopathy (23, 24) , attenuated mutant ␣-MHC promoters (17) were used to achieve a low level of h-␤2AR expression (18) . Immunoblotting of h-␤2AR transgenic myocardia detected h-␤2AR as a broad Ϸ70-kDa band accompanied by higher molecular weight species previously identified as glycosylated forms (25) (Fig. 2A) . [ 125 I]-cyanopindolol binding capacity was 760 Ϯ 111 fmol͞mg in the lower expressors (Ϸ35-fold NTG and 1,350 Ϯ 57 fmol͞mg in the higher expressors (Ϸ70-fold NTG). Compartmentation was determined by buoyancy density fractionation over discontinuous (5%͞30%͞40%) sucrose gradients into light, medium, or heavy endosomes. Caveolin-3, a muscle-specific marker for lipid-rich plasma membrane invaginations (26) , was enriched at the interface between the 5% and 30% gradients (Fig. 2B , fractions 3 and 4), whereas alkaline phosphatase (plasma membranes) was at the 30 -40% interface and clathrin was enriched in the pellet (not shown). Markers for Golgi, endoplasmic reticulum, and lysosomes were in fractions 7-10 (data not shown). h-␤2AR were located primarily in the heavier 40% gradient fractions (fractions 7-10), although some also copurified with caveolin (Fig. 2B) . Endogenous Rab4, a marker for recycling vesicles (16, 22) , localized to fractions 7-10, whereas Rab5 (Fig. 2B ) and transferrin receptor (not shown) marked early endosomes (27, 28) at the interface between intermediate and heavy density gradients (fractions 6 and 7). As with h-␤2AR, G␤ and the G␣s subunits of heterotrimeric G proteins were in heavier endosomal fractions of NTG mice (Fig.  2C ). G␣s had a broader distribution in h-␤2AR overexpressing hearts, most likely because of its association with overexpressed receptors (Fig. 2C) .
The effects of agonists on subcellular distribution of h-␤2AR and G protein effectors were assessed before and after 5-min infusion of high-dose isoproterenol. Agonist stimulation provoked receptor translocation from heavier to lighter, caveolin-enriched fractions (Fig. 3A) . In contrast, G␣s remained in the heavier fractions, consistent with a previously postulated role for caveolar uncoupling of ␤2AR from effectors (29) . Rab-specific effects on ␤2AR trafficking were assessed in Q72L and S27N Rab4 transgenic mice crossbred with h-␤2AR overexpressors and compared with receptor translocation by isoproterenol (Fig. 3C, ␤2AR-35 and ␤2AR-35 ϩ Iso). Neither Rab mutant affected the level of h-␤2AR overexpression (data not shown). However, dominant inhibition of Rab4 (S27N) recapitulated agonist-induced subcellular redistribution (Fig. 3C, ␤2AR-35͞Rab4S27N) , and Rab4 activation (Q72L) resulted in accumulation of h-␤2AR in the lighter sucrose fractions (Fig. 3C, ␤2AR-35͞Rab4Q72L) .
Functional consequences of Rab4-mediated ␤AR compartmentation were assessed. As previously reported (18, 23, 30) , h-␤2AR overexpression enhanced basal left ventricular systolic function (percent of fractional shortening and ϩdP͞dt), compared with NTG (compare Tables 1 and 2 ). Constitutive activation of Rab4 with the Q72L mutant had no effect on these parameters. In contrast, expression of inhibitory S27N Rab4 significantly depressed both inotropic indices (Table 2) . Together, these data show that inhibition of Rab4 diminishes ␤2AR-mediated cardiac contractile function through redistribution of ␤AR in a manner analogous to that occurring after agonist exposure. Indeed, evidence of altered ␤AR trafficking was v isualized by confocal microscopy. In h-␤2AR-overexpressing mice representing the normal pattern of ␤2AR compartmentation, there was highly defined labeling of sarcolemma and transverse tubular structures (Fig. 4A) , consistent with sarcolemmal localization (31) . In contrast, Rab4 S27N͞h-␤2AR cardiomyocytes exhibited granular cytoplasmic staining and coarse labeling of sarcolemma and transverse tubules, suggesting subsarcolemmal vesicular localization of receptors (Fig. 4 A) . Consistent with this notion, ultrastructural examination revealed abnormal cytoplasmic and subsarcolemmal vesicular structures in compound Rab4 S27N͞h-␤2AR (Fig. 4B ) and Rab4 S37N (data not shown) hearts, compared to normal-appearing structures in NTG, h-␤2AR, Rab4 Q72L͞ h-␤2AR (Fig. 4B) , and Rab4 Q72L (data not shown) hearts.
Given that Rab4 regulates receptor insertion into membranes (21, 22) and in vivo myocardial Rab4 inhibition resulted in ␤AR insensitivity, we hypothesized that myocardial Rab4 mediates ␤AR recycling after agonist-mediated internalization (resensitization). Therefore, we assayed in vivo cardiac desensitization after 20 min of high-dose isoproterenol, and measured time-dependent functional recovery. As in Fig. 1B , Rab4 S27N mice had depressed responsiveness to isoproterenol, compared with NTG or Rab4 Q72L (Fig. 5) . Corrected for this basal abnormality, desensitization (percentage of initial agonist response) was 49% and 62% in NTG and Q72L mice, respectively, but was complete (i.e., no agonist response) in S27N. Additionally, there was no significant resensitization (normalization of agonist response) in S27N mice, versus functional recovery after 30 min of 57% and 65% in NTG and Q72L mice, respectively. Thus, the phenotype of myocardial Rab4 activation is ␤2AR translocation with normal function, whereas that of Rab4 inhibition is ␤2AR insensitivity because of impaired receptor resensitization through defective receptor recycling.
Discussion
These studies establish a necessary role for Rab4-mediated ␤AR sarcolemmal targeting in cardiac adrenergic responsiveness and resensitization. Depressed inotropic indices with Rab4 inhibition in the conscious, unsedated mouse suggest that ␤AR internalization and reinsertion occur continuously under physiological in vivo conditions. The combination of GRK-mediated receptor-effector uncoupling, ␤-arrestinstimulated receptor internalization, and Rab4-mediated resensitization therefore constitute a highly regulated mecha- nism for modulating myocardial adrenergic responsiveness through adjustments of adrenergic receptor homeostasis.
To interrogate ␤AR trafficking in the in vivo heart, we modified a Rab small G protein thought to regulate receptor movement from endosomes to plasma membranes (21, 22) . Emerging data indicate that individual Rab proteins control distinct vesicular transport events in a highly specific manner by binding to donor vesicles, facilitating transport, and modulating docking and fusion to targets (15, 32) . Expression in cultured fibroblasts has shown that Rab5 regulates protein internalization into early endosomes, whereas Rab4 regulates vesicular transport from endosomes to plasma membranes (27, 28) . Although Rab1 transgenesis caused cardiomyopathy associated with disordered Golgi (20) (consistent with Rab1 regulation of transGolgi transport; see ref. 33 ), mutant Rab4 mice showed no evidence of cardiac pathology, only diminished catecholamine-stimulated myocardial function with Rab4 inhibition.
To define ␤AR trafficking events that could account for impaired cardiac function of Rab4 S27N, we used antibodybased techniques and a low-expressing transgenic h-␤2AR mouse (18) . An advantage of combining the ␣MHC-driven Rab4 and h-␤2AR transgenic models is that receptors and Rab4 mutants were located exclusively in cardiac myocytes, which eliminates potentially confounding effects of other myocardial cell types. Also, endogenous mouse ␤1AR and ␤2AR were not visualized by using the human receptorspecific antibody. Compound h-␤2AR͞Rab4 S27N mice revealed an association between functional inhibition and translocation of ␤2AR to caveolin-rich endosomal fractions. This pattern of receptor trafficking recapitulated redistribution of ␤2AR with agonist, but was associated with loss of agonist responsiveness and blunting of the hallmark intrinsic cardiac activation of ␤2AR overexpression (23, 24) . In contrast, ''recycling activated'' Rab4 Q72L͞h-␤2AR compound transgenic, exhibited normal ␤2AR responsiveness, and appropriate inotropic enhancement with h-␤2AR overexpression. Fig. 6 depicts our concept of Rab4-mediated ␤AR trafficking in context of these phenotypes. Although our use of overexpressed receptors to track Rab4-mediated trafficking events has the potential to exaggerate uncoupled, or ''spare'' receptor effects, we suggest that activation of Rab4 (Fig. 6 Upper, Q72L) accelerates ␤AR reinsertion into plasma membranes where it functions normally. Agonist stimulation causes normal caveolar translocation and desensitization, but because internalized receptors are rapidly reinserted, there is also rapid resensitization. In contrast, inhibition of Rab4 (Fig. 6 Lower, S27N) prevents ␤AR recycling, causing receptor accumulation in caveolae and early endosomes, where receptors cannot interact with G protein effectors, and adrenergic insensitivity. Agonist-mediated translocation of receptors to caveolae increases endosomal accumulation of receptors and reinforces the phenotype by preventing resensitization.
Independent of Rab4 activity, our findings in h-␤2AR overexpressing hearts indicate that in vivo cardiac ␤2AR [like ␤1AR in cultured cardiac myocytes (29) ] colocalize with G␣s, Rab4, and Rab5 in plasma membranes and endosomes but translocate to fractions enriched in caveolae within minutes of agonist simulation. This finding is consistent with previously described agonist-induced caveolar targeting of m2 muscarinic and kinin B1 receptors (34, 35) but differs from prior descriptions of cardiomyocyte ␤2AR as being located entirely in the caveolar-rich fractions of cultured neonatal rat cardiomyocytes (29, 31) . Although the h-␤2AR transgenic model may, like any overexpression or transfection system, generate nonphysiological results, other possible explanations for these differences include species differences between rodent and human ␤2AR, developmental differences between neonatal and adult cardiomyocytes (25) , the total absence of intrinsic catecholamine stimulation and contractile activity in quiescent tissue culture, and altered ␤2AR localization after enzymatic cardiomyocyte isolation (25) . Reports of apparent caveolar egress of ␤2AR after agonist stimulation in cultured cardiomyocytes (29) , compared with our observation of caveolar targeting of ␤2AR after isoproterenol stimulation in intact hearts, are more readily explained. The prolonged (30-min) period of isoproterenol exposure in the tissue culture study likely induced receptor internalization (36) , explaining the loss of receptors from caveolae.
In summary, these studies reveal a critical function for trafficking of ␤2AR in maintaining normal myocardial responsiveness to catecholamines and in promoting adrenergic resensitization after sustained adrenergic stimulation. Our data suggest that ␤AR internalization and reexpression occur continuously to maintain proper adrenergic responsiveness in the in vivo heart. Given reports of regulated Rab protein expression in heart failure (20) and the recently described existence of polymorphic human ␤AR exhibiting abnormal receptor internalization or trafficking (␤1AR Gly 49 and ␤2AR Glu 27 and Arg 16 variants) (37) , these data support a contributory role for altered ␤AR recycling in cardiomyopathic syndromes.
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